

for the Treatment of Alzheimer's Disease; *Use:* CMS Office of Minority Health (OMH) is going to announce a call for nominations for the 2024 CMS Health Equity Award. This award will recognize organizations who demonstrate they have advanced health equity by designing, implementing, and operationalizing policies and programs that support health for all the people served by our programs, reducing avoidable differences in health outcomes experienced by people who are underserved, and provided the care and support that CMS enrollees need to thrive.

The goals of the award are to encourage organizations to identify and address their health disparities, to disseminate best practices, and to show that progress is possible by having a results-oriented focus. By identifying organizations who are successfully closing gaps and reducing disparities, CMS can show our stakeholders how health equity work can be initiated, targeted, measured, and successfully reduce disparities among communities nationwide.

CMS Representatives collect Company Name, Point of Contact Information (email, phone# & name) along with information from the organizations regarding their programs to improve the health quality, outcomes, and access to care for the communities that they serve. The CMS selection committee uses a scoring rubric to score the applicants on demonstrated measurable results in reducing a disparity in one or more of the CMS priority populations. *Form Number:* CMS-10866 (OMB control number: 0938-NEW); *Frequency:* Annually; *Affected Public:* Federal Government, Business or other for-profits and Not-for-profit institutions; *Number of Respondents:* 50; *Number of Responses:* 50; *Total Annual Hours:* 100. (For policy questions regarding this collection, contact Ashley Peddicord-Austin at 410-786-0757.)

Dated: September 1, 2023.

William N. Parham, III,

Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2023-19359 Filed 9-7-23; 8:45 am]

BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Announcing the Intent To Award a Single-Source Supplement for the Alternatives to Guardianship Youth Resource Center Cooperative Agreement

ACTION: Notice.

SUMMARY: The Administration for Community Living (ACL) announces the intent to award a single-source supplement to the current cooperative agreement held by the University of Massachusetts for the Alternatives to Guardianship Youth Resource Center cooperative agreement. The purpose of this project is to divert high school students with intellectual and developmental disabilities (I/DD) away from guardianship to less restrictive decisional supports. The target audience for this information includes youth with I/DD, families, and caregivers of high school students with I/DD, teachers, education administrators, advocates, vocational rehabilitation counselors, guidance counselors, and school district officials. The administrative supplement for FY 2023 will amount to \$200,000, bringing the total award for FY 2023 to \$500,000.

FOR FURTHER INFORMATION CONTACT: For further information or comments regarding this program supplement, contact Dana Fink, U.S. Department of Health and Human Services, Administration for Community Living, Administration on Disabilities, (202) 795-7604 or via email dana.fink@acl.hhs.gov.

SUPPLEMENTARY INFORMATION: This supplementary funding will expand the Alternatives to Guardianship Youth Resource Center's engagement and education efforts around diverting high school students with I/DD away from guardianship to less restrictive decisional supports. As a result of funding this Center, ACL expects that:

- More students with I/DD will have more decisional options, such as Powers of Attorney, supported-decision-making, joint bank accounts, bill paying services, and medical or educational release forms, on completion of high school;
- Fewer young adults with I/DD will be subject to guardianship;
- The public will become more knowledgeable of alternatives to guardianship; and
- Youth will become more independent by gaining job experience and personal responsibilities.

This supplement will fund:

- Support to enhance the engagement of youth advisory board members, including (1) a dedicated staff member for facilitation and administrative coordination and support and; (2) paid opportunities for youth advisory board members to be more deeply engaged in project activities.

- Continued support for two additional staff members from grant partner Self-Advocates Becoming Empowered who have joined the youth ambassador training team.

- Additional training for project staff and partners on allyship and augmentative and alternative communication (AAC) to support a state team of AAC users.

- Support for travel for youth ambassadors and youth advisors to participate in conference presentations.

- Supervisory support for the new youth trainer position that will begin August 2023. This youth trainer will join the Youth Ambassador workgroup and be part of the training team that facilitates the third cohort of youth ambassadors from Texas, California, and New York.

- Continued enhancement to the project website, which includes a dedicated page for each of the 40+ youth ambassadors, youth-friendly products and videos, and plain language documents.

The administrative supplement for FY 2023 will amount to \$200,000, bringing the total award for FY 2023 to \$500,000.

Program Name: Center for Youth Voice Youth Choice (CYVYC) Alternatives to Guardianship Youth Resource Center.

Recipient: University of Massachusetts, Boston.

Period of Performance: The supplement award will be issued for the fourth year of the five-year project period of September 1, 2023, through August 31, 2024.

Total Supplement Award Amount: \$200,000.

Award Type: Cooperative Agreement.

Statutory Authority: This program is authorized under the Developmental Disabilities Assistance and Bill of Rights Act of 2000 Pub. L. 106-402, Section 161(2) (B), (C) and (D).

Basis for Award:

The University of Massachusetts is currently funded to carry out the CYVYC Project for the period of September 1, 2020 through August 31, 2025. Much work has already been completed and further tasks are currently being accomplished. It would be unnecessarily time consuming and disruptive to the CYVYC project and the beneficiaries being served for ACL to establish a new grantee at this time

when critical services are presently being provided in an efficient manner.

Dated: September 4, 2023.

Alison Barkoff,

Senior official performing the duties of the Administrator and the Assistant Secretary for Aging.

[FR Doc. 2023–19391 Filed 9–7–23; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–D–3518]

Endogenous Cushing's Syndrome: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Endogenous Cushing's Syndrome: Developing Drugs for Treatment.” The purpose of this guidance is to provide recommendations to sponsors regarding clinical trial designs for drugs intended for the treatment of adults with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative. This draft guidance is intended to focus continued discussions among FDA's Division of General Endocrinology, pharmaceutical sponsors, the academic community, and the public.

DATES: Submit either electronic or written comments on the draft guidance by November 7, 2023 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or

anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2023–D–3518 for “Endogenous Cushing's Syndrome: Developing Drugs for Treatment.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as

“confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT:

Naomi Lowy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301–796–0692.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled “Endogenous Cushing's Syndrome: Developing Drugs for Treatment.” The purpose of this guidance is to provide recommendations to sponsors regarding clinical trial designs for drugs intended for the treatment of adults with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative. This draft guidance is intended to focus continued discussions among FDA's Division of General Endocrinology, pharmaceutical sponsors, the academic community, and the public. This is the first guidance drafted by FDA on this topic.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on “Endogenous Cushing's Syndrome: